
Kardigan
Kardigan is a patient-driven heart health company that is modernizing cardiovascular drug development to deliver medicines that move patients beyond symptom management to functional cures. By matching critical disease drivers with treatment responders identified in clinical trials, Kardigan is developing a portfolio of medicines that modify the underlying cardiovascular disease pathophysiology to get patients closer to the cures they deserve. Kardigan has significant East and West Coast operatio
- Total raised
- $554M
- Latest round
- Series B
- Employees
- 240
Funding & revenue at Kardigan
How well capitalized the business is — useful context before you scope a fractional engagement or negotiate a rate.
Total capital raised
$554M
5 known investors
Latest round
Series B · $254M
Oct 2025
Publicly traded
KARD
IPO Jun 2026
Investors
Growth signals
How fast Kardigan is adding people, roles, and audience.
Employees
240
Reported band 51-200
Open roles
1
-0.9% year over year
LinkedIn followers
11.4K
+123% year over year
Headcount change
- MoM
- +5.7%
- +13 people
- QoQ
- +10.1%
- +22 people
- 6mo
- +33.3%
- +60 people
- YoY
- +67.8%
- +97 people
- 2yr
- +433.3%
- +195 people
Team composition
Where Kardigan concentrates its people — a read on which function a fractional leader would plug into.
By function
- Research4218%
- Business Development2812%
- Operations188%
- Human Resources167%
- Information Technology125%
- Program And Project Management115%
- Legal104%
- Quality Assurance83%
By region
- United States232
- California, United States119
- San Francisco Bay Area115
- New York City Metropolitan Area49
- New Jersey, United States43
- Greater Philadelphia27
Inside Kardigan
What the business focuses on, where it operates, and how employees rate it.
Categories
Markets
Offices
- , South San Francisco, California, US
Kardigan in the news
Recent coverage picked up alongside the firmographic refresh.
- Kardigan reports net loss of USD 8.6M in Q3 2026
Nov 2026
- Kardigan (NASDAQ:KARD) Given New $36.00 Price Target at Leerink Partners
Nov 2026
- Kardigan 3Q 2026: EPS ($0.64) — 10-Q Summary
Nov 2026
- Kardigan Reports Third Quarter 2026 Financial Results and Recent Business Updates
Nov 2026
- Kardigan to Participate in the Jefferies Global Healthcare Conference
Nov 2026
- Kardigan Extends Phase 2 Ataciguat Trial Assessment, Targets 2027 Results
Nov 2026
Jobs
1Funding, revenue, headcount, and hiring figures are third-party estimates from public sources and are not confirmed by the company. Last refreshed November 20, 2026.
About this page
This company page is automatically generated based on publicly available job postings. Company information is sourced from publicly available data and may not be complete. If you represent Kardigan, you can claim this page to manage and enhance it.